Fusion Antibodies plc
Results of voting at Annual General Meeting on 23 September 2022
All resolution proposed at the AGM were passed on a poll. The results of the voting are set out below. Any votes that were for the discretion of the Chair have been included in the votes 'for'.
Percentage of votes cast | |||||
Resolution | Outcome | Votes cast | For | Against | |
Ordinary Resolutions | |||||
1. | To receive the Company's annual | ||||
accounts and the strategic, | Passed | 7,800,587 | 99.99% | 0.01% | |
directors' and auditor's reports | |||||
for the year ended 31 March | |||||
2022 | |||||
2. | To reappoint Adrian Kinkaid, | ||||
who retires in accordance with | Passed | 8,576,156 | 99.99% | 0.01% | |
the Articles of Association, as a | |||||
director | |||||
3. | To reappoint Matthew Baker, | ||||
who retires by rotation, as a | Passed | 8,576,156 | 99.42% | 0.58% | |
director | |||||
4. | To reappoint Simon Douglas, | ||||
who retires by rotation, as a | Passed | 8,576,156 | 96.30% | 3.70% | |
director | |||||
5. | To reappoint Richard Buick, who | ||||
retires by rotation, as a director | Passed | 8,576,156 | 96.30% | 3.70% | |
6. | To reappoint | ||||
PricewaterhouseCoopers LLP as | Passed | 8,323,181 | 99.75% | 0.25% | |
auditors | |||||
7. | To authorise the Audit | ||||
Committee to determine the | Passed | 8,576,156 | 99.99% | 0.01% | |
remuneration of the auditors | |||||
8. | To authorise the directors to | ||||
allot relevant securities of up to | Passed | 8,576,156 | 99.99% | 0.01% | |
a nominal value of £346,865.92, | |||||
subject to certain conditions | |||||
Special Resolutions | |||||
9. | To empower the directors to | ||||
allot relevant securities of up to | Passed | 8,530,531 | 99.22% | 0.78% | |
a nominal value of £104,059.76 | |||||
on a non-pre-emptive basis | |||||
subject to certain conditions | |||||
10.To authorise the Company to | |||||
make market purchases of up to | Passed | 7,046,097 | 99.09% | 0.91% | |
2,601,494 ordinary shares | |||||
subject to certain conditions |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fusion Antibodies plc published this content on 23 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 October 2022 15:59:08 UTC.